Coherus matches Mylan on pegfilgrastim price

Coherus BioSciences will match the US list-price discount offered by Mylan for biosimilar pegfilgrastim versus the reference brand when it begins shipping the firm's Udenyca (pegfilgrastim-cbqv) on 3 January 2019. Like Biocon's Fulphila (pegfilgrastim-jmdb) that partner Mylan launched earlier this year, Udenyca will be priced at US$4,175 per pre-filled syringe, a 33% discount to Neulasta's wholesale acquisition cost (WAC). "Beyond list price, we also have contracting plans that we believe will deliver additional value to payers, providers and patients in the long term, facilitating uptake," Coherus revealed.